Form 4: ARS Pharmaceuticals CLO Sells Shares via 10b5-1 Plan

Chief Legal Officer Alexander A. Fitzpatrick sold 3,355 shares of ARS Pharmaceuticals common stock under a pre-arranged trading plan.

Summary

• Alexander A. Fitzpatrick, Chief Legal Officer of ARS Pharmaceuticals, Inc. (SPRY), sold 3,355 shares of common stock.
• The transaction occurred on June 12, 2026, at a price of $10.00 per share.
• Following the sale, the reporting person retains beneficial ownership of 90,910 shares.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a small portion of the executive's total holdings.

Positives

• The transaction was conducted under a pre-established Rule 10b5-1 trading plan, which is designed to avoid concerns regarding insider trading.

Negatives

• The sale represents a reduction in the equity stake held by a key member of the executive management team.

Risks

• Continued selling by insiders may be perceived negatively by retail investors, potentially impacting short-term stock sentiment.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard corporate governance practice and typically does not signal a lack of confidence in the company's long-term prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to liquidate equity positions while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was executed through a pre-planned mechanism.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

SPRY, ARS Pharmaceuticals, Insider Trading, Form 4, Chief Legal Officer, Equity Sale